Drug Profile


Alternative Names: Irminix; NBMI; OSR#l

Latest Information Update: 02 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Kentucky
  • Developer EmeraMed Limited
  • Class Benzene derivatives; Small molecules; Sulfhydryl compounds
  • Mechanism of Action Antioxidants; Chelating agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Heavy metal poisoning
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Chronic obstructive pulmonary disease; Heavy metal poisoning

Most Recent Events

  • 05 Jul 2016 Phase-II clinical trials in Chronic obstructive pulmonary disease in Sweden (PO) (EudraCT2016-001805-18)
  • 23 Jan 2016 EmeraMed Limited completes enrolment in its phase IIa trial for Heavy metal poisoning in Ecuador
  • 31 Aug 2015 Phase-IIa clinical trials in Heavy metal poisoning in Ecuador (PO) (NCT02486289)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top